Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 15/20 | 0.60 |
| ▸ | CDK4 | P11802 | 3/20 | 0.39 |
| ▸ | CCND1 | P24385 | 3/20 | 0.39 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.38 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.38 |
| ▸ | CDK2 | P24941 | 2/20 | 0.38 |
| ▸ | PRKACA | P17612 | 1/20 | 0.38 |
| ▸ | PRKACG | P22612 | 1/20 | 0.38 |
| ▸ | PRKACB | P22694 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5869886 | 0.88 | TOP1 (0.60) | TOP1CDK4CCND1PRKCQCCNE2 | |
| SCHEMBL7264159 | 0.88 | TOP1 (0.61) | TOP1CDK4CCND1PRKCQCCNE2 | |
| SCHEMBL5869577 | 0.86 | TOP1 (0.66) | TOP1CDK4CCND1PRKCQCCNE2 | |
| SCHEMBL5870176 | 0.82 | TOP1 (0.65) | TOP1CDK4CCND1PRKCQCCNE2 | |
| SCHEMBL7030485 | 0.78 | TOP1 (0.74) | TOP1CDK4CCND1PRKCQCCNE2 | |
| SCHEMBL7862848 | 0.78 | TOP1 (0.72) | TOP1CDK4CCND1CCNE2CCNE1 | |
| SCHEMBL5668292 | 0.77 | TOP1 (0.65) | TOP1CDK4CCND1PRKCQCCNE2 | |
| SCHEMBL5666583 | 0.77 | TOP1 (0.65) | TOP1CDK4CCND1PRKCQCCNE2 | |
| SCHEMBL5666580 | 0.77 | TOP1 (0.67) | TOP1CDK4CCND1CCNE2CCNE1 | |
| SCHEMBL5668290 | 0.77 | TOP1 (0.67) | TOP1CDK4CCND1CCNE2CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7138377-B2 | Topoisomerase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-21 | — | — | US | disclosed |
| US-20030203860-A1 | Substituted sugar derivatives of indolopyrrolocarbazoles, useful in inhibiting the proliferatin of tumor cells | BRISTOL-MYERS SQUIBB COMPANY | 2003-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203860-A1 | Substituted sugar derivatives of indolopyrrolocarbazoles, useful in inhibiting the proliferatin of tumor cells | TYMP, MKI67, CCNI | TOP1 5/4885CDK4 7/4885CCND1 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.